Roivant to Acquire Silicon Therapeutics for ~$450M

 Roivant to Acquire Silicon Therapeutics for ~$450M

Roivant to Acquire Silicon Therapeutics for ~$450M

Shots:

  • Roivant to acquire Silicon for $450M in Roivant’s equity with additional potential regulatory and commercial milestones. The acquisition will strengthen Roivant’s AI capabilities for drug discovery
  • The acquisition of Silicon will bolster Roivant’s targeted protein degradation platform that will be powered by VantAI’s ML techniques
  • The integration of Silicon and VantAI will allow Roivant to leverage both computational physics and machine learning-based approaches to drug design

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post